MARKET

NVAX

NVAX

Novavax Inc
NASDAQ
5.68
+0.09
+1.61%
Opening 14:49 12/06 EST
OPEN
5.56
PREV CLOSE
5.59
HIGH
5.82
LOW
5.56
VOLUME
4.18M
TURNOVER
0
52 WEEK HIGH
18.55
52 WEEK LOW
5.30
MARKET CAP
674.73M
P/E (TTM)
-0.8908
1D
5D
1M
3M
1Y
5Y
Canadian regulators authorize updated Novavax COVID-19 vaccine
Healthcare canadian regulators authorize updated novavax covid-19 vaccine. The vaccine will be available in the comings days in canada for people aged 12 and older. The product is also authorized for use in the us, eu and by the world health organization.novavax said it has received expanded authorization from canadian regulators for its updated vaccine.
Seeking Alpha · 22h ago
Novavax Says Updated COVID-19 Vaccine Now Authorized In Canada
Benzinga · 23h ago
Novavax Inc: Current report
Press release · 1d ago
Novavax settles class action lawsuit over COVID vaccine for $47M
Healthcare novavax settles class action lawsuit over covid vaccine for $47m. Lawsuit was filed in 2021 by sothinathan sinnathurai. Novovax made purportedly false and misleading statements about its covid-19 vaccine claims, the lawsuit alleges.
Seeking Alpha · 1d ago
Weekly Report: what happened at NVAX last week (1127-1201)?
Weekly Report · 2d ago
Is Novavax Stock a Buy Now?
Biotech company novavax's stock is down 94% in the past three years. The company is one of the leaders in the covid-19 vaccine market. In the third quarter, the company's revenue was much lower than last year. Novavox's guidance for 2023 doesn't inspire much confidence.
The Motley Fool · 4d ago
'Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization In The Republic Of Korea' - Novavax
Benzinga · 6d ago
Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use
NASDAQ · 11/29 16:53
More
About NVAX
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.

Webull offers Novavax Inc stock information, including NASDAQ: NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVAX stock methods without spending real money on the virtual paper trading platform.